EHA 2023 | REVIVE: targeted therapy for uncontrolled erythrocytosis in PV with rusfertide

Elevated hematocrit is a hallmark of polycythemia vera (PV), and it is associated with higher rates of death. Whilst it is essential to maintain hematocrit levels below 45% to decrease the risk of thrombotic and cardiovascular events, current standards of care (SOC) are not effective in the majority of patients. In this presentation, Ronald Hoffman, MD, presents results from the REVIVE study (NCT04057040), which evaluated the efficacy of rusfertide, a novel hepcidin mimetic, in patients with PV. The study met its primary endpoint of maintaining hematocrit levels below 45% and demonstrated that rusfertide was highly efficacious in controlling erythrocytosis. The data from the randomized withdrawal phase demonstrated the superior efficacy of rusfertide in eliminating the need for additional therapeutic phlebotomies as compared to placebo. Rusfertide therapy was associated with persistent hematocrit (HCT) control and improvements in PV-related symptoms. The treatment was generally well tolerated. The positive outcomes of the REVIVE study showcase the efficacy and tolerability of rusfertide as a highly effective therapy for uncontrolled erythrocytosis and associated symptoms in PV, and is currently being investigated in the ongoing Phase III VERIFY study (NCT05210790). This press briefing took place at the European Hematology Association (EHA) Congress 2023, held in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.